



0300

ATTORNEY DOCKET NO. 036870-5062-01 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael ZASLOFF, *et al.*

Application No.: 09/885,247

Filed: July 13, 2000

For: THERAPEUTIC USES FOR
AMINOSTEROL COMPOUNDS

Commissioner for Patents
Washington, D.C. 20231

Group Art Unit: 1614

Examiner: Unassigned

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b)(3), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are enclosed. Applicants respectfully request that the Examiner consider the listed documents and indicate that the documents have been considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies the document as "prior art" against any claims in the application and Applicants determine that the cited document does not constitute "prior art"


under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Jeffrey N. Townes
Reg. No. 47,142

Date: July 24, 2002

MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Ave., N.W.
Washington, D.C. 20004
(202) 739-3000
(202) 739-3001

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) JUL 24 2002 PTO Form 1449	Attorney Docket No. 036870-5062-01	Serial No. 09/885,247
	Applicant: Michael Zasloff, et al.	
	Filing Date: July 13, 2000	Group: 1614

U.S. PATENT DOCUMENTS

* Examiner Initial	Document Number	Date (mm-dd-yy)	Name	Class	Sub Class	Filing Date
	5,763,430	Jun. 9, 1998	Zasloff	514	169	Jun. 7, 1995
	5,847,172	Dec. 8, 1998	Zasloff	552	521	Jun. 7, 1995

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Document Number	Date (month-day-year)	Country	Class	Sub Class	Translation YES NO
WO 96/40728	Dec. 19, 1996	PCT			
WO 96/40151	Dec. 19, 1996	PCT			
WO 96/44044	Nov. 27, 1997	PCT			
WO 98/19682	May 14, 1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Zasloff, et al., "A spermine-coupled cholesterol metabolite from the shark with potent appetite suppressant and antidiabetic properties," <u>International Journal of Obesity</u> (2002), 25(5), pages 689-697
	Zasloff, et al., "A centrally acting cholesterol metabolite with potent appetite suppressant and antidiabetic properties," <u>Pediatric Research</u> , (April 2002), Vol. 47, No. 4, Part 2, Page 142A

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	